The global smart pills market size was valued at USD 1.67 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 11.4% from 2023 to 2030. High demand for minimally invasive procedures, increased focus on patient convenience, and technological development, including miniaturization of integrated circuits, are factors that are expected to drive market growth. According to the National Center for Biotechnology Information (NCBI), over the course of 18 years, from 2000 to 2018, the U.S. witnessed a significant 50% increase in the number of minimally invasive procedures performed. In 2018 alone, the country recorded a remarkable total of over 15 million minimally invasive procedures. Among these procedures, laparoscopic cholecystectomy (gallbladder removal), appendectomy, and hernia repair are the most common ones. These minimally invasive techniques have gained popularity due to their numerous advantages over traditional open surgery.
Demand for advanced drug delivery systems with benefits such as optimal use of the active pharmaceutical ingredients, reduced dosage frequency, minimal adverse/side effects, targeted drug delivery, and safer carrier is driving the market for smart pills. The integration of innovative drugs, medical devices, and advanced technologies is expected to play an important role in further boosting the market over the forecast period. Patients with chronic diseases who need to follow a specific dose of medication at the target site are expected to form a large customer base for advanced drug delivery products.
For instance, in April 2023, the Da Vinci Xi Robotic Surgical System was launched by Apollo to offer cutting-edge technology and advancements in surgical procedures. The Da Vinci Xi system facilitates minimally invasive surgeries, where only small incisions are made. This results in less trauma to the patient reduced pain, and quicker recovery times compared to traditional open surgeries. The system's advanced technology helps in achieving better surgical outcomes. Its 3D high-definition vision system offers a clearer view of the surgical site, and the instruments' articulating capabilities allow for more precise tissue manipulation and suturing.
High demand for minimally invasive surgical procedures has given rise to innovative techniques such as capsule endoscopy. With advantages such as ease of administration and detailed observation of the gastrointestinal tract, capsule endoscopy is expected to replace traditional endoscopy methods.
According to NCBI, the U.S. is expected to experience a significant demographic shift over the coming decades. The number of individuals aged 50 and older is projected to surge by 61.11%, rising from 137.25 million in 2020 to 221.13 million by 2050. With this aging population, there is a concerning increase in the prevalence of chronic diseases. The number of people aged 50 years and older with at least one chronic condition is estimated to rise by 99.5%, reaching 142.66 million by 2050, compared to 71.522 million in 2020. Moreover, the burden of multimorbidity is also expected to grow substantially. Individuals with multimorbidity, meaning they have two or more chronic diseases, are projected to increase by 91.16% from 7.8304 million in 2020 to 14.968 million in 2050.
Potential customers of smart pills include patients with paralysis, immobile patients, and the geriatric population. Growth in the geriatric population is expected to fuel the demand for advanced medical devices designed to increase the convenience of patients. According to the report from United Nations, over the past century, the world's population has experienced significant growth, expanding more than threefold. As of mid-November 2022, the global human population stands at approximately 8.0 billion, a considerable increase from the estimated 2.5 billion in 1950. In just over a decade, from 2010 to 2022, we witnessed an addition of 1 billion individuals, and since 1998, the population has grown by 2 billion.
Moreover, experts project that the world's population will continue to increase, with nearly 2 billion more people expected to be added over the next 30 years. This trajectory is predicted to raise the current population of 8 billion to 9.7 billion by 2050, and there is a possibility of reaching a peak of nearly 10.4 billion around the mid-2080s. Such population growth poses challenges and opportunities for sustainability, resource management, and global development in the future.
Based on the application, the market for smart pills is segmented into products, tools, and patient monitoring software. The product segment captured a significant revenue share in 2022 and includes the actual pill or capsule being swallowed by patients. Factors, such as the disposable nature of capsules, repeat usage, and high cost is anticipated to enable the product segment to grow its dominance throughout the forecast period. The capsule endoscopy segment is expected to grow owing to the incidence of gastrointestinal disorders, such as colon cancer, Crohn's disease, and ulcerative colitis, which is increasing globally. This is driving the demand for minimally invasive diagnostic procedures, such as capsule endoscopy. According to the Crohn's & Colitis Foundation, in the U.S., about 1 in 100 individuals are affected by inflammatory bowel disease (IBD), a group of chronic gastrointestinal disorders. Crohn's disease, which falls under the category of IBD, equally impacts both men and women, and it can develop at any age. However, it is most commonly diagnosed in adolescents and young adults, typically between 20 and 30 years old. Studies have shown a genetic factor associated with IBD development, as between 1.5 percent and 28 percent of individuals with IBD have a close family member (parent, child, or sibling) who also experiences one of these diseases.
According to NCBI, in 2019, digestive diseases were responsible for approximately 2,276.27 million prevalent cases, 2.56 million deaths, and 88.99 million DALYs (Disability-Adjusted Life Years) worldwide. These numbers showed a significant increase of 67.87% in cases, 37.85% in deaths, and 23.47% in DALYs compared to 1990. Moreover, the cases of digestive diseases also rose from 254.25 million in 1990 to 443.53 million in 2019.
North America dominates the market for smart pills in terms of revenue, accounting for a share of over 35% in 2022. The region is expected to retain its lead throughout the forecast period owing to factors such as technological advancements in the healthcare sector, an increase in the incidence of colorectal cancer, and regulatory approval of new products. According to WHO, Colorectal cancer holds the position of being the third most prevalent cancer across the globe, accounting for around 10% of all cancer cases, and is also the second leading cause of cancer-related deaths worldwide. It primarily affects older individuals, with the majority of cases occurring in people aged 50 years and above. The development of colorectal cancer is influenced by several lifestyle factors, such as a diet high in processed meats and low in fruits and vegetables, a sedentary lifestyle, obesity, smoking, and excessive alcohol consumption.
Asia Pacific is expected to be the fastest-growing segment with a CAGR of 12.9% over the forecast period Asia Pacific is expected to grow significantly in the coming years, especially in Japan, China, and India. Key factors driving the Japan market include mandatory healthcare insurance, technological advancements, and an increase in the prevalence of stomach cancer and gastrointestinal disorders. In 2020, there were over one million newly reported cases of gastric cancer worldwide, resulting in 769,000 deaths. Among the regions with the highest incidence rates are certain Asian countries, notably Japan, Mongolia, and China. While the overall incidence of gastric cancer has been decreasing, there has been a concerning rise in cases among young adults over the past few decades. Estimating the burden of gastric cancer remains challenging, particularly in high-prevalence countries in Asia.
Key players in the market are focusing on adopting growth strategies, such as mergers and acquisitions, developing existing devices, promotional events, and technological advancements. For instance, in 2022, Semaglutide, an anti-diabetes pill from Novo Nordisk, has been launched in India, providing a fresh treatment alternative for individuals dealing with type 2 diabetes. As a glucagon-like peptide (GLP-1) receptor analog molecule, semaglutide shows great promise as an addition to diabetes management approaches.
Report Attribute |
Details |
Market size value in 2023 |
USD 1.88 billion |
Revenue forecast in 2030 |
USD 4.09 billion |
Growth rate |
CAGR of 11.4% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
November 2023 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, region |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France, Italy; Spain; Denmark; Sweden; Norway; Japan, China; India; Australia; Thailand; South Korea; Mexico; Brazil; Argentina; Chile; Colombia; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Medtronic; Otsuka Holdings Co., Ltd.; CapsoVision, Inc.; Olympus Corporation; Medisafe |
Customization scope |
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail of customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global smart pills market report based on application, and region:
Application Outlook (Revenue, USD Million, 2018 - 2030)
Product
Capsule Endoscopy
Drug Delivery
Tools
Patient Monitoring System
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global smart pills market size was estimated at USD 1.67 billion in 2022 and is expected to reach USD 1.88 billion in 2023.
b. The global smart pills market is expected to grow at a compound annual growth rate of 11.4% from 2023 to 2030 to reach USD 4.09 billion by 2030.
b. North America dominated the smart pills market with a share of 38.12% in 2022. This is attributable to technological advancements in the healthcare sector, an increase in the incidence of colorectal cancer, and regulatory approval of new products.
b. Some key players operating in the smart pills market include Medtronic PLC; Proteus Digital Health; CapsoVision, Inc.; Olympus Corporation; and Medisafe.
b. Key factors that are driving the market growth include increasing prevalence of diseases such as colorectal cancer and gastrointestinal disorders, expansion in the geographical reach of major players, rising cancer screening awareness programs, and expeditious FDA approvals.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."